One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Acumen Pharmaceuticals, Inc.
ABOS · NMS · Healthcare · Biotechnology
Current price
$0.24
52-week range
$0.19 - $3.60
Market cap
$17.14M
Balance sheet
Healthy
-29.32x Concerning
Net cash $52.29M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -162.7% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 6.8% (peer median: 11.8%).
What this company does
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a drug development company working on a new treatment for Alzheimer's disease. Their main product, sabirnetug, is a special type of medicine that is currently in testing, and the money they make will likely come from future sales if their drug is approved. This matters because successful drug development could lead to significant revenue and help many people suffering from Alzheimer's.
How the company got here
Acumen Pharmaceuticals was founded in 1996 by scientists who pioneered research into toxic soluble amyloid beta oligomers (AβOs), which they believe are a key cause of Alzheimer's disease. The company has focused on developing therapies that target these AβOs. Over the years, Acumen has advanced its lead drug candidate, sabirnetug (ACU193), through various stages of clinical trials, including Phase 1 and Phase 2 studies. They have also entered into collaborations to explore different formulations and delivery methods for their therapies, aiming to improve their effectiveness in treating Alzheimer's disease.
What it actually does
Acumen Pharmaceuticals is a biopharmaceutical company that works on developing medicines to treat Alzheimer's disease. Their main focus is on creating a specific type of drug, called a monoclonal antibody, that targets and neutralizes harmful protein clumps in the brain known as amyloid beta oligomers (AβOs). The idea is that by clearing these AβOs, they can slow down or prevent the nerve cell damage that leads to Alzheimer's symptoms.
Sabirnetug (ACU193) Program
This is Acumen's primary business line, centered around their investigational drug candidate, sabirnetug (ACU193). Sabirnetug is a type of therapy called a monoclonal antibody, which is designed to specifically target and bind to toxic soluble amyloid beta oligomers (AβOs) in the brain. These AβOs are believed to be a key factor in the development and progression of Alzheimer's disease. The company has been conducting clinical trials, such as the Phase 2 ALTITUDE-AD study, to evaluate the safety and effectiveness of sabirnetug in patients with early Alzheimer's disease. This program represents the core of Acumen's efforts to develop a disease-modifying treatment for Alzheimer's.
Enhanced Brain Delivery (EBD) Program
Acumen is also developing an Enhanced Brain Delivery (EBD) program, which aims to improve how their Alzheimer's therapies reach the brain. This involves combining their targeted antibody therapies with technologies designed to help them cross the blood-brain barrier more effectively. They are collaborating with other companies, like JCR Pharmaceuticals, to utilize specialized delivery systems. The goal of this program is to potentially increase the amount of drug that gets into the brain and reaches the areas where it's needed, thereby enhancing the treatment's impact. This represents a secondary but important area of development for Acumen, focusing on optimizing drug delivery for neurological conditions.
What management is betting on now
Acumen's management is focused on advancing its drug candidates through clinical trials to demonstrate their potential to treat Alzheimer's disease. A key priority is the successful completion and analysis of the Phase 2 ALTITUDE-AD study for sabirnetug, which is expected to provide crucial data on its efficacy and safety. Simultaneously, they are investing in the development of their Enhanced Brain Delivery (EBD) program, aiming to create next-generation therapies with improved brain penetration. These efforts are geared towards establishing Acumen as a leader in developing innovative treatments for Alzheimer's and addressing the significant unmet medical need in this area.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-27.21M
FY2025 Q1
$-34.20M
FY2025 Q2
$-31.84M
FY2025 Q3
$-30.49M
FY2025 Q4
$-19.10M
FY2026 Q1
$-24.13M
FY2026 Q2
$-18.07M
FY2026 Q3
$-26.65M
Revenue
—
Net income
$-25.37M
Diluted EPS
-0.35
Operating cash flow
$-26.65M
Free cash flow
$-26.65M
Fetching…
Sources
Revenue
—
Net income
$-32.72M
Diluted EPS
-0.45
Operating cash flow
$-18.07M
Free cash flow
$-18.07M
Fetching…
Sources
Revenue
—
Net income
$-20.74M
Diluted EPS
-0.33
Operating cash flow
$-24.13M
Free cash flow
$-24.13M
Fetching…
Sources
Revenue
—
Net income
$-25.14M
Diluted EPS
-0.40
Operating cash flow
$-19.10M
Free cash flow
$-19.10M
Fetching…
Sources
Revenue
—
Net income
$-26.45M
Diluted EPS
-0.44
Operating cash flow
$-30.49M
Free cash flow
$-30.49M
Fetching…
Sources
Revenue
—
Net income
$-40.95M
Diluted EPS
-0.68
Operating cash flow
$-31.83M
Free cash flow
$-31.84M
Fetching…
Sources
Revenue
—
Net income
$-28.80M
Diluted EPS
-0.48
Operating cash flow
$-34.12M
Free cash flow
$-34.20M
Fetching…
Sources
Revenue
—
Net income
$-37.15M
Diluted EPS
-0.62
Operating cash flow
$-27.21M
Free cash flow
$-27.21M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.24
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $52.3M - more cash than debt. Interest coverage -29.3x.
Net debt
$-52.29M
Interest coverage
-29.32x
Acumen Pharmaceuticals, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
ABOS
BASELINE
Acumen Pharmaceuticals, Inc.
Total debt $26.31M Interest coverage -29.32x This is the baseline the peer rows are being compared against.
Total debt $589.00K Interest coverage -1,876.38x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -42.48x Neither company has much profit cushion over interest right now.
Total debt $6.26M Interest coverage -13.05x Neither company has much profit cushion over interest right now.
What you should know
The case for and against ABOS
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -162.7% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 6.8% (peer median: 11.8%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.49x
P/B
0.49x
P/S
—
EV/EBITDA
0.34x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-162.7%
ROA
-57.5%
Health
Liquidity and balance-sheet strength
Debt / equity
0.76x
Current ratio
1.89x
Quick ratio
1.79x
Total debt
$26.31M
Total cash
$78.60M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-1.55
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-87.95M
Free CF TTM
$-115.63M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—